Clinical Research

** Now Open For Enrollment **
Janssen Research & Development, LLC / “A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus”

**Now Open ForEnrollment**
GlaxoSmithKline / “A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104- Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)”

**Now Open For Enrollment**
Part A
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

Part B
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

**Now Open ForEnrollment**
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerabilityand efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

**Now Open For Enrollment**
A RANDOMIZED DOUBLE-BLIND PHASE 1b/2 COMBINED STAGGERED MULTIPLE DOSE ESCALATION STUDY OF BOS161721 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS ON A BACKGROUND OF LIMITED STANDARD OF CARE

PATIENT INFORMATION DOCUMENTS